Senate Republicans Blame Medicaid for the Rise in Opioid Deaths

Sen. Ron Johnson, R-Wis.

Sen. Ron Johnson, R-Wis. (AP Photo/J. Scott Applewhite)

 

Connecting state and local government leaders

But the data and the on-the-ground experience of local health officials beg to differ.

WASHINGTON — Republicans in the U.S. Senate are trying out an interesting scapegoating tactic when it comes to the escalation of the nation’s opioid crisis. They are pointing the finger of blame at Medicaid, the federal-state program that provides health care coverage to millions of low-income Americans.

On Wednesday, the Senate Homeland Security and Governmental Affairs Committee, chaired by Wisconsin Republican Ron Johnson, held a hearing with the stated intention of revealing the “unintended consequences” of Medicaid with regard to the nationwide epidemic.

And, a report from Johnson, also released on Wednesday, links Medicaid and expansion of the program under the Affordable Care Act with the increase in overdose deaths.

The gist of that report—and the line of questioning from many of the Republican senators during Wednesday’s hearing—was essentially this: that Medicaid has increased patients’ access to prescription opioid drugs, which are then abused and diverted to the black market, fueling both the rise in addiction and death. This isn’t the first time Johnson and other Republican lawmakers have floated this claim.

In late July 2017, at the height of the GOP push to repeal and replace the Affordable Care Act, Johnson wrote a letter to the Health and Human Services Department’s inspector general alleging a correlation between Medicaid expansion and opioid overdoses. “Because opioids are so available and inexpensive through Medicaid,” Johnson wrote, “it appears that the program has created a perverse incentive for people to use opioids, sell them for large profits, and stay hooked.”

And it isn’t just conservative lawmakers in Congress who are trying out this argument. Louisiana’s Republican attorney general, Jeff Landry, asserted in November that his state’s decision to expand Medicaid had fueled its opioid crisis. “A program that just gives away drugs, without the proper protocols in place, certainly has exacerbated this condition,” Landry said.

The Data Tells a Different Story—in Louisiana, and Across the Nation

In response to Landry’s claim, Esteban Gershanik, the Louisiana Department of Health and Hospitals’ chief information officer told WAFB-TV, the local CBS affiliate in Baton Rouge: “I don't know where the Attorney General got his numbers.

According to Gershanik, the number of opioid pills being prescribed is actually on the decline in in Louisiana. At the time, the Louisiana Board of Pharmacy Prescription Monitoring Program projected the number of prescriptions per 100 Louisiana citizens in 2017 to be around 109. That’s a decrease from 113 in 2015 and 110 in 2016, the year the state’s Medicaid expansion went into effect.

“Those things that often make you addicted—the amount of opioid pills and the number of opioid pills—has decreased by 25 percent over the past three months,” Gershanik said in November.

Louisiana isn’t the only place where the causal relationship between Medicaid expansion and the opioid crisis appears tenuous, at best. Across the country, the argument that Medicaid expansion catalyzed or worsened the overdose crisis crumbles with an examination of the timeline and evolution of the epidemic.

The Timeline Argument

Conservative pundits and politicians are trying to establish a connection between the ACA’s Medicaid expansion and a rise in overdose deaths related to the opioid crisis.

During Wednesday’s hearing, Sam Adolphsen, a senior fellow at the Foundation for Government Accountability—an organization whose stated mission is to equip policymakers “with principled strategies to replace failed health and welfare programs nationwide”—testified that 13 of the 15 states with the highest age-adjusted rates of opioid overdose deaths are Medicaid expansion states.

“This correlation is deeply concerning. Is the addition of tens of millions of able-bodied adults to Medicaid partly responsible for the opioid crisis?” Adolphsen asked.

While there might be a correlation here, researchers have been unable to show any causation. In August 2017, partly in response to Johnson’s aforementioned letter, Andrew Goodman-Bacon, an assistant professor of economics at Vanderbilt University, and Emma Sandoe, a health policy Ph.D student at Harvard University, took on an analysis of the available evidence that the Medicaid expansion caused the opioid epidemic, and published their findings in Health Affairs. Their conclusion: “there’s little evidence” to support that claim.

Goodman-Bacon and Sandoe found that the claim that expansion of Medicaid caused or exacerbated the opioid epidemic is not credible for three primary reasons:

First, trends in opioid deaths nationally and by Medicaid expansion status predate the ACA. Second, counties with the largest coverage gains actually experienced smaller increases in drug-related mortality than counties with smaller coverage gains. Third, the fact that Medicaid recipients fill more opioid prescriptions than non-recipients largely reflects greater levels of disability and chronic illness in the populations that Medicaid serves. While we do not reject the possibility that public policy has played a role in our current prescription abuse crisis, on balance we find little evidence to support the idea that Medicaid caused or worsened the epidemic.

The timeline argument—that the worsening of the opioid epidemic predates the move by states to expand Medicaid—is perhaps the most persuasive. This chart, for example, shows that the states that would later go on to expand Medicaid were seeing higher rates of drug poisoning mortality years before expansion began in 2014.

(Health Affairs)

The Trends Argument

The timeline isn’t the only data point that simply doesn’t match up to this GOP claim. The evolution of the epidemic itself has meant that prescription painkillers, like the ones conservative pundits argue were newly available to Medicaid beneficiaries following expansion, are not the driving force behind the recent surge in deaths.

Experts and the data agree: the catalyst behind skyrocketing overdose deaths is not prescription painkillers. Instead, devastatingly deadly synthetic opioids like fentanyl and carfentanil are to blame.

Research has shown that, in fact, the number of opioid painkiller prescriptions being written is on the decline. While prescribing remains alarmingly high in many parts of the nation, since a peak in 2010, the U.S. has seen year-after-year reductions in the writing of these prescriptions. And the results of that decline in prescribing are born out in the latest mortality data.

Age-adjusted drug overdose death rates, by opioid category: United States, 1999–2016

(SOURCE: NCHS, National Vital Statistics System, Mortality)

As the chart from the U.S. Centers for Disease Control and Prevention shows above, while deaths related to natural and semisynthetic opioids—a category that includes prescription painkillers—have mostly plateaued, deaths related to synthetics like fentanyl have exponentially increased. In fact, these types of deaths increased so rapidly that the rate of such overdoses doubled in a single year from 3.1 per 100,000 in 2015 to 6.2 in 2016.

If Medicaid expansion, and the resulting access to prescription drugs, were to blame for the spike in overdose deaths, we would be looking at a very different chart, with prescription drugs leading the pack in terms of cause of death.

The View From the Trenches

Health officials and advocates would disagree with the conservative assessment of Medicaid’s role in the crisis for another reason: they have seen what Medicaid expansion has done, and the impact the program has had on connecting those suffering from substance abuse disorders with treatment.

An analysis by the Kaiser Family Foundation found that a growing number of nonelderly adult Americans are having their opioid addiction treatment covered by the federal program—26 percent of were receiving treatment covered by the program in 2005, 10 years later that percentage had doubled:

(Kaiser Family Foundation)

“Medicaid expansion has been, from my perspective in the trenches, the most powerful tool that we have policy-wise to get people into recovery,” Dr. Michael Brumage, the executive director and health officer of the Kanawha-Charleston Health Department in West Virginia, told Route Fifty in a phone interview on Wednesday.

“Expanding access to services has been beneficial to get people who would otherwise be in the shadows of the opioid epidemic into treatment,” Brumage added.

Quinn Libson is a Staff Correspondent for Government Executive’s Route Fifty and is based in Washington, D.C.

FEATURED CASE STUDIES
Powered By The Atlas
Expanding broadband access with small cell deployment in City of Ontario
Ontario, CA, USA
Laguna Beach open 24/7/365 for business license renewals!
Laguna Beach, CA, USA
Scottsdale tracks strategic plan to better share progress with City Council, staff and residents
Scottsdale, AZ, USA

NEXT STORY: Unanswered Questions Surround Work Requirements for Federal Housing Aid

X
This website uses cookies to enhance user experience and to analyze performance and traffic on our website. We also share information about your use of our site with our social media, advertising and analytics partners. Learn More / Do Not Sell My Personal Information
Accept Cookies
X
Cookie Preferences Cookie List

Do Not Sell My Personal Information

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about the First and Third Party Cookies used please follow this link.

Allow All Cookies

Manage Consent Preferences

Strictly Necessary Cookies - Always Active

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data, Targeting & Social Media Cookies

Under the California Consumer Privacy Act, you have the right to opt-out of the sale of your personal information to third parties. These cookies collect information for analytics and to personalize your experience with targeted ads. You may exercise your right to opt out of the sale of personal information by using this toggle switch. If you opt out we will not be able to offer you personalised ads and will not hand over your personal information to any third parties. Additionally, you may contact our legal department for further clarification about your rights as a California consumer by using this Exercise My Rights link

If you have enabled privacy controls on your browser (such as a plugin), we have to take that as a valid request to opt-out. Therefore we would not be able to track your activity through the web. This may affect our ability to personalize ads according to your preferences.

Targeting cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.

Social media cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your browser across other sites and building up a profile of your interests. This may impact the content and messages you see on other websites you visit. If you do not allow these cookies you may not be able to use or see these sharing tools.

If you want to opt out of all of our lead reports and lists, please submit a privacy request at our Do Not Sell page.

Save Settings
Cookie Preferences Cookie List

Cookie List

A cookie is a small piece of data (text file) that a website – when visited by a user – asks your browser to store on your device in order to remember information about you, such as your language preference or login information. Those cookies are set by us and called first-party cookies. We also use third-party cookies – which are cookies from a domain different than the domain of the website you are visiting – for our advertising and marketing efforts. More specifically, we use cookies and other tracking technologies for the following purposes:

Strictly Necessary Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Functional Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Performance Cookies

We do not allow you to opt-out of our certain cookies, as they are necessary to ensure the proper functioning of our website (such as prompting our cookie banner and remembering your privacy choices) and/or to monitor site performance. These cookies are not used in a way that constitutes a “sale” of your data under the CCPA. You can set your browser to block or alert you about these cookies, but some parts of the site will not work as intended if you do so. You can usually find these settings in the Options or Preferences menu of your browser. Visit www.allaboutcookies.org to learn more.

Sale of Personal Data

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Social Media Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.

Targeting Cookies

We also use cookies to personalize your experience on our websites, including by determining the most relevant content and advertisements to show you, and to monitor site traffic and performance, so that we may improve our websites and your experience. You may opt out of our use of such cookies (and the associated “sale” of your Personal Information) by using this toggle switch. You will still see some advertising, regardless of your selection. Because we do not track you across different devices, browsers and GEMG properties, your selection will take effect only on this browser, this device and this website.